Hims & Hers Health (HIMS.US) has announced the introduction of affordable treatment options for individuals experiencing perimenopause and menopause. This launch expands the company's business into the realm of hormone replacement therapy. The stock briefly surged over 20% during trading and closed up 16.18% on Wednesday, although it dipped 1.93% in after-hours trading. Hims & Hers anticipates that this new specialized service will help its "Hers" division achieve its goal of over $1 billion in annual revenue next year. The company stated that patients can collaborate with healthcare providers on its platform to receive treatment plans for menopause and perimenopause (the phase before menstruation ceases), including prescriptions, patches, or creams. According to the company, these treatment plans may involve hormones such as estradiol and progesterone. Estradiol can alleviate symptoms like hot flashes and night sweats, while progesterone can help improve sleep quality and protect the uterine lining.